Danaher Corporation (DHR) Q3 2025 Financial Results Summary
Release Date: October 21, 2025
Danaher Corporation has reported its financial results for the third quarter ending September 26, 2025. Below is a summary of the key metrics and highlights from the report.
Key Financial Highlights
- Net Earnings:
- $908 million, or $1.27 per diluted common share
-
Non-GAAP adjusted diluted net earnings per common share: $1.89 (up from $1.71 a year ago)
-
Revenue:
- Total revenues increased 4.5% year-over-year to $6.1 billion
-
Non-GAAP core revenue increased 3.0% year-over-year
-
Cash Flow:
- Operating cash flow reported at $1.7 billion
-
Non-GAAP free cash flow at $1.4 billion (up from $1.226 billion a year ago)
-
Operating Profit:
-
$1.154 billion, compared to $958 million in the same quarter last year, indicating a growth of 20.5%
-
Gross Profit:
-
$3.523 billion, up from $3.401 billion a year ago
-
Income Tax Expense:
-
$168 million, compared to $159 million in Q3 2024
-
Total Cash Flow Activities:
- Net cash provided by operating activities: $1.662 billion, compared to $1.513 billion the same period last year
Segment Performance
- Total Company Sales Growth:
-
4.5% increase compared to the same period in 2024
-
Segment-wise Sales Growth:
- Biotechnology: 9.0% increase
- Life Sciences: 0.5% increase
-
Diagnostics: 4.0% increase
-
Core Sales Growth (non-GAAP):
- 3.0% increase for total company
- 6.5% growth in Biotechnology
- -1.0% decline in Life Sciences
- 3.5% growth in Diagnostics
Full-Year 2025 Outlook
- Guidance:
- Danaher maintains its adjusted diluted net earnings per common share guidance in the range of $7.70 to $7.80
-
Non-GAAP core revenue is expected to grow in the low-single digits year-over-year
-
Currency Impact:
- Estimated to influence sales by approximately 1.0% year-over-year
Dividends and Share Repurchase
-
Dividend Declaration: There is no mention of a quarterly dividend in this report.
-
Share Repurchase: No share repurchase activity was disclosed in this report.
Management Comments
Rainer M. Blair, Danaher’s President and CEO, emphasized the company’s focus on delivering value through investment in innovation, enhancing commercial execution, and driving productivity gains across its business segments. The company’s strategic execution has led to better-than-expected performance, particularly in bioprocessing and respiratory revenue streams.
Conclusion
Danaher Corporation’s third quarter results showcase a robust increase in profits, revenues, and cash flow, marking a solid performance as they navigate their portfolio’s growth through strategic execution and continued investment in innovation. The outlook for the remainder of 2025 remains stable with expectations for revenue growth and effective financial management. For more detailed information, stakeholders are encouraged to view the full report and attend the earnings conference call.
Here are the extracted tables from the provided press release:
CONSOLIDATED CONDENSED STATEMENTS OF EARNINGS
(amounts in millions)
| Three-Month Period Ended | Nine-Month Period Ended | |||
|---|---|---|---|---|
| September 26, 2025 | September 27, 2024 | September 26, 2025 | September 27, 2024 | |
| Sales | $6,053 | $5,798 | $17,730 | $17,337 |
| Cost of sales | -$2,530 | -$2,397 | -$7,173 | -$7,021 |
| Gross profit | $3,523 | $3,401 | $10,557 | $10,316 |
| Operating costs: | ||||
| Selling, general and administrative | -$1,991 | -$2,060 | -$6,209 | -$5,736 |
| Research and development expenses | -$378 | -$383 | -$1,160 | -$1,142 |
| Operating profit | $1,154 | $958 | $3,188 | $3,438 |
| Nonoperating income (expense): | ||||
| Other income (expense), net | -$14 | $102 | -$135 | $7 |
| Interest expense | -$67 | -$87 | -$210 | -$217 |
| Interest income | $3 | $4 | $17 | $103 |
| Earnings before income taxes | $1,076 | $977 | $2,860 | $3,331 |
| Income taxes | -$168 | -$159 | -$443 | -$518 |
| Net earnings | $908 | $818 | $2,417 | $2,813 |
| Net earnings per common share: | ||||
| Basic | $1.28 | $1.13 | $3.38 | $3.83 |
| Diluted | $1.27 | $1.12 | $3.37 | $3.80 |
| Average common stock and common | ||||
| equivalent shares outstanding: | ||||
| Basic | 710.7 | 723.0 | 714.5 | 733.8 |
| Diluted | 713.7 | 729.4 | 717.9 | 740.1 |
CONDENSED CONSOLIDATED BALANCE SHEETS
(amounts in millions)
| September 26, 2025 | December 31, 2024 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $1,635 | $985 |
| Accounts receivable, net | $3,480 | $3,161 |
| Inventories | $2,081 | $2,188 |
| Other current assets | $460 | $345 |
| Total current assets | $7,656 | $6,679 |
| Property, plant and equipment, net | $3,242 | $3,658 |
| Goodwill | $9,673 | $9,915 |
| Other intangible assets, net | $1,514 | $1,629 |
| Other assets | $587 | $495 |
| Total assets | $22,672 | $22,376 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Short-term borrowings | $228 | $138 |
| Current portion of long-term debt | $956 | $1,024 |
| Accounts payable | $2,948 | $2,728 |
| Other current liabilities | $1,439 | $1,385 |
| Total current liabilities | $5,571 | $5,275 |
| Long-term debt | $5,923 | $6,220 |
| Deferred income taxes | $602 | $645 |
| Other long-term liabilities | $243 | $80 |
| Total liabilities | $12,339 | $12,220 |
| Stockholders’ equity | ||
| Common stock and additional paid-in capital | $1,018 | $997 |
| Retained earnings | $8,880 | $8,141 |
| Accumulated other comprehensive income | $435 | $318 |
| Total stockholders’ equity | $10,333 | $9,456 |
| Total liabilities and stockholders’ equity | $22,672 | $22,376 |
